|Day Low/High||93.97 / 94.77|
|52 Wk Low/High||58.59 / 95.44|
Microsoft and Celgene both look like they want to fill a gap higher.
Biotech is conspicuously weak, with weakness in Allergan , Celgene and Gilead Sciences . I suspect we could see tax selling in December, but it's still early. Speculative biotech is not much better. I am avoiding the sector for now.
On Thursday, I waved the white flag exited my AGN position.
To me, there are a number of important lessons in Allergan's $11 drop today: There is no substitute for objective and hard-hitting security analysis. A variant view can be special and deliver alpha -- it can contribute importantly to avoiding los...
Despite stocks near their all-time records, there are more potholes (this week) than observed on Second Avenue in the Upper East Side in New York City. Today's potholes: * Optical (Oclaro guidedown) * FANG (reaction to earnings) * Retail (again) *...
Looking ahead, Allergan may be more vulnerable than suggested by management or believed by analysts.
The very fact that contrarian investing is hard makes it an effective strategy since it is done by so few investors.
The fundamentals are there, supported by earnings. Let's look at the charts.
It depends on which aisle of the stock market you're on.
LGI Homes, ANI Pharmaceuticals and Sonus Networks are worth considering.
The stocks of Amgen, Celgene and Gilead Sciences all took hits after posting quarterly results.
The ECB's super dovish message was good for the markets.
Shares of DowDuPont jumped after issuing preliminary third-quarter results.
An observation: Despite being within 1% of the all-time high in the S&P Index, this week's feature was a number of investment potholes --relatively large sized individual fundamental disappointments followed by marked stock price drops. Celgene , B...
What was dangerous is now safe, what was safe is now risky.
A frequent theme of mine is the lack of follow-up and accountability by commentators and "talking heads" in the media of the many ideas that have soured. Losers are part of the game -- and those who don't confess to mistakes are either lying or, as...
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Thursday's trending stocks.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer doesn't advise panicking over Celgene.
Breadth is positive, but pockets of momentum are very limited.
This morning I added to Allergan on weakness in biotech -- a true contrarian and counterintuitive bet considering the struggles of Celgene et al. However, I am still only medium in size in my AGN position.
The Summit, N.J.-based firm on Oct. 26 unveiled third-quarter results and updated its 2017 outlook and financial targets for 2020.
As an observation, I find -- and this is characteristic of a mature bull market -- that many investors, strategists, commentators and talking heads are just taking shots in the dark on stocks these days and are not adjusting their outlooks for chang...
Celgene is down around $13 in premarket trading after disappointment over its third-quarter results. This stock has been widely heralded on "Fast Money" and elsewhere, mostly on technical grounds. But I must say, our Bobby Lang showed a lot of ...
The forces that artificially impacted the marketplace return to normal; so will the marketplace itself.
With thirty minutes to go: * Watching CNBC and the rest of the business media, one would conclude that "everyone is in the pool." It is, as one talking head just declared..."a buy/buy scenario." (Enough said/written). * The bond market's decline was...